DCPH Deciphera Pharmaceuticals Inc.

35.67
-0.24  -1%
Previous Close 35.91
Open 36.07
Price To Book 8.11
Market Cap 1,806,597,716
Shares 50,647,539
Volume 58,326
Short Ratio
Av. Daily Volume 871,325

NewsSee all news

  1. Deciphera Pharmaceuticals Announces Late-Breaking Oral Presentation of Pivotal Phase 3 INVICTUS Data at the European Society for Medical Oncology (ESMO) 2019 Congress

    Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that data from the Company's INVICTUS pivotal

  2. Deciphera Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares in Public Offering of Common Stock

    Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that the underwriters of its previously announced

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 additional data due 2H 2019.
DCC-3014
Solid tumors or hematological malignancies
Phase 3 data met PFS primary endpoint - August 13, 2019. Secondary ORR endpoint not achieved. Presentation at ESMO September 30, 2019, 2:25pm CEST.
Ripretinib DCC-2618 - INVICTUS
Gastrointestinal Stromal Tumors (GIST) - fourth-line
Phase 3 trial initiation announced December 20, 2018.
DCC-2618 - INTRIGUE
Gastrointestinal Stromal Tumors (GIST) - second-line
Phase 1b trial complete.
Rebastinib
Breast Cancer
Phase 2 part of trial to commence 2Q 2019. Part 1 data due 2H 2019.
Rebastinib and paclitaxel
Solid tumors
Phase 1b/2 trial initiation announced January 3, 2019.
Rebastinib and carboplatin
Solid tumors
Phase 1 updated data released August 13, 2019. ORR 8-22%.
Ripretinib DCC-2618
Gastrointestinal Stromal Tumors (GIST) - second-fourth line

Latest News

  1. Deciphera Pharmaceuticals Announces Late-Breaking Oral Presentation of Pivotal Phase 3 INVICTUS Data at the European Society for Medical Oncology (ESMO) 2019 Congress

    Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that data from the Company's INVICTUS pivotal

  2. Deciphera Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares in Public Offering of Common Stock

    Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that the underwriters of its previously announced